From Greffex, May 15, 2017
Greffex, Inc. and the Texas A&M University System (TAMUS) are excited to announce a collaboration on advanced process and manufacturing development. This agreement will advance the research and development of Greffex vaccines and assist the Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM) at TAMUS to establish a robust, efficient pipeline of countermeasures to public health emergencies both in the US and worldwide.
From the press release:
“As we prepare for the next phase of research and development, we needed a creative, innovative “university-based” partner to assist us in our long-range development plans,” said John R. Price, President and CEO of Greffex, “and in Texas A&M Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM), we found the creative, forward-thinking researchers who can leverage the resources of the entire university system.”